New Treatments Could Be Powerful Weapons Against Brain Tumors
WEDNESDAY, Aug. 14, 2019 (HealthDay News) -- New therapies are showing real promise in fighting the type of brain cancer that claimed the lives of Sens. John McCain and Ted Kennedy, a pair of new clinical trials shows.
One experimental treatment injects powerful genes directly into a brain tumor, and then uses pills to turn the genes on and off. That way, the genes can attack the cancer without going berserk and damaging other parts of the body.
"It's the first time where we show you can do drug-induced gene therapy," said lead researcher Dr. Antonio Chiocca, neurosurgeon-in-chief and chair of neurosurgery at Brigham and Women's Hospital in Boston. "You don't want these genes to express all the time. Here we show for the first time in humans, you can turn a gene on and off based on a drug the patient takes by mouth."
Meanwhile, the other new therapy uses mild electrical current to reduce blood flow to brain tumors, starving the cancer of the nutrients it needs to grow.
Glioblastoma, the form of brain cancer under study, is tough to fight. Traditional therapy involves surgery, radiation and chemotherapy, Chiocca said.
Even with that, half of patients die on average within about 15 months, and the cancer usually recurs within seven months, he noted.
"When it comes back, median survival is usually only a few months," Chiocca said.
In the gene study, Chiocca and his colleagues injected brain tumors with viruses carrying a gene that promotes the production of interleukin-12, a biochemical that prompts the immune system to find and fight cancer.
Interleukin-12 (IL-12) can't be directly administered to patients because it's so powerful that it runs amok in the body, causing side effects like kidney and liver failure, Chiocca explained.
But the IL-12 genes placed in the tumor were genetically altered so that they could be switched on and off using a new drug called veledimex, Chiocca said.
"The patient takes it by mouth and it crosses into the brain, into the tumor, and turns on the gene for a period of hours," Chiocca said of veledimex.
The phase I trial involved 31 patients with recurring glioblastoma. Results showed that the genes safely promoted an immune response against brain tumors, the researchers said.
These sorts of tumors typically are found to be "immune-deserted," with no immune cells at all within them, Chiocca said.
But, "when we looked at the tissue, it was full of immune cells" following treatment, he reported.
While the genes stimulated IL-12 production in the tumors, the powerful biochemical did not appear to enter the bloodstream and circulate throughout the body, the researchers said.
Some patients exhibited serious side effects, including reduced counts of various blood cells, increases in liver enzymes, and an immune system overreaction called "cytokine release syndrome."
But the side effects went away after the patients stopped taking veledimex, and were less severe in patients taking a lower dose of the drug, the study authors explained.
Future clinical trials will judge the effectiveness of this gene therapy, but Chiocca is hopeful.
Patients who received the gene therapy and also took a powerful steroid called dexamethasone "lived the longest, about 17 months after treatment, which historically is pretty long," he said. "With these recurrent glioblastomas, we measure survival in a range of 3 to 6 months."
One neurosurgeon had high praise for the study.
Dr. Michael Schulder, vice chair of neurosurgery at North Shore University Hospital in Manhasset, N.Y., and Long Island Jewish Medical Center in New Hyde Park, N.Y., said the gene study is "very exciting" with "impressive science behind it."
"The fact is their patients did live longer than expected at the time of glioblastoma recurrence," Schulder said, adding that he looks forward to seeing the results of larger trials aimed at testing the treatment's effectiveness.
A neuro-oncologist also awaits larger trials.
"Obviously further head-to-head study is required to see if this is an efficacious strategy for the majority of glioblastoma patients," said Dr. Stephanie Weiss, chief of neurologic oncology at Fox Chase Cancer Center in Philadelphia. "However, it's a promising proof of principle that immunologic therapies can be delivered to brain tumor patients who thus far have not benefited from the emerging field of immunotherapy."
In the second study, an international research team found that placing electrodes on the head of a patient can help reduce blood flow to brain tumors.
The researchers administered mild electrical stimulation for 20 minutes to 18 patients with brain cancer. MRI scans showed that less blood flowed into the tumor tissue, without affecting the rest of the brain.
"Chemotherapies can have some, though typically limited, efficacy in the brain, due to the blood-brain barrier," Weiss said. "More novel therapies such as immunomodulation also have some limited efficacy in the brain. More recently, there has been evidence that the manipulation of alternating electrical fields could have some efficacy in the treatment of brain tumors."
The new studies were published Aug. 14 in the journals Science Translational Medicine and Science Advances.
The American Brain Tumor Association has more about glioblastomas.
SOURCES: Antonio Chiocca, M.D., Ph.D., neurosurgeon-in-chief and chair, neurosurgery, Brigham and Women's Hospital, Boston; Michael Schulder, M.D., vice chair, neurosurgery, North Shore University Hospital, Manhasset, N.Y., and Long Island Jewish Medical Center, New Hyde Park, N.Y.; Stephanie Weiss, M.D., chief, neurologic oncology, Fox Chase Cancer Center, Philadelphia; Aug. 14, 2019, Science Translational Medicine; Aug. 14, 2019, Science Advances